GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types

Philipp Sievers(German Cancer Research Center), Felix Sahm(German Cancer Research Center), Guido Reifenberger(Düsseldorf University Hospital), Dominik Sturm(German Cancer Research Center), Jonas Ecker(German Cancer Research Center), Martin Hasselblatt(University Hospital Münster), Albrecht Stenzinger(Heidelberg University), Daniel Schrimpf(German Cancer Research Center), Bastiaan B.J. Tops(Radboud University Nijmegen), Till Milde(German Cancer Research Center), Evelina Miele(Bambino Gesù Children's Hospital), Andrey Korshunov(Ontario Institute for Cancer Research), Mariëtte E.G. Kranendonk(Princess Máxima Center), David Capper(German Cancer Research Center), Stefan M. Pfister(Heidelberg University), Pieter Wesseling(Radboud University Nijmegen), Andreas von Deimling(German Cancer Research Center), Rudi Beschorner(Brain (Germany)), Daniel Kazdal(Heidelberg University), Patricia Kohlhof‐Meinecke(Klinikum Stuttgart), Florian Selt(German Cancer Research Center), Wolfgang Wick(German Cancer Research Center), Martin Sill(German Cancer Research Center), David Jones(German Cancer Research Center), Damian Stichel(German Cancer Research Center), Olaf Witt(German Cancer Research Center), Christof M. Kramm(Universitätsmedizin Göttingen)

Acta Neuropathologica

September 18, 2021

Cited by 23

Related Papers

|Nature|2013|10.1k

|Nature|2018|3.1k

|Nature Reviews Clinical Oncology|2020|1.9k

|Journal of Clinical Oncology|2010|1.4k

|Nature|2017|1.2k